Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.

Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as Jiuzhitang Maker), established in March 2018 with a registered capital of 200 million yuan, is a biotechnology company dedicated to the production, research and development, and sales of stem cell-based pharmaceuticals and regenerative medicine products. Jiuzhitang Maker has already built a large-scale stem cell drug R&D and manufacturing facility—meeting GMP standards set by China, the U.S., and the EU—at the Beijing Daxing Biomedical Base, known as "China Pharmaceutical Valley." The facility boasts an office and production area of approximately 4,800 square meters, featuring four independent B+A-grade clean zones capable of producing clinical-grade stem cell drugs that comply with both Chinese and U.S. regulatory requirements for pharmaceutical submissions.

Jiuzhitang Maker has introduced stem cell technology from the U.S.-based Stemedica Cell Technologies, further refining and enhancing it to develop a unique stem cell production and quality system.

Jiuzhitang Maker has been recognized as one of the "Ten Key Enterprises" by both the Daxing District Development and Reform Commission and the Biomedical Base Committee. The company has also earned prestigious accolades, including titles such as "Zhongguancun High-Tech Enterprise," "National High-Tech Enterprise," "Zhongguancun Golden Seed Enterprise," "First Batch of Science and Technology-Based SMEs Granted Entry into Ministry of Science and Technology Facilities," "Postdoctoral Research Workstation," "District-Level Enterprise R&D Institution," and "Beijing Specialized, Fine, and Innovative Enterprise." Additionally, Jiuzhitang Maker was honored with the title "Top 50 Innovative Chinese Biopharmaceutical Companies in 2020," "Outstanding Corporate Social Responsibility Enterprise of 2020," the "2021 Award for Growth Potential among Chinese Biopharmaceutical Companies," and two major awards at the 5th Brand Power China Economic Forum in 2021. Furthermore, the company played a key role in drafting the group standard titled "Guidelines for Ethical Evaluation of Stem Cell Sources."

In February 2020, Jiuzhitang Maker’s clinical trial for a new stem-cell-based drug received approval (Acceptance No.: JXSL1900126), targeting ischemic stroke as its indication. This marks the first clinical trial approved by the CDE to utilize imported stem cells, the first to explore stem cells for treating major neurological conditions, and the first to employ bone marrow-derived mesenchymal stem cells. As such, it holds landmark significance for the development of China’s stem-cell industry. On January 12, 2021, the ASSIST clinical trial officially kicked off and is currently being conducted at several hospitals, including Beijing Tiantan Hospital, Affiliated to Capital Medical University.

In June 2023, Jiuzhitang Maker received approval (Acceptance No.: CXSL2300202) for the clinical trial of its second stem-cell-based innovative drug, targeting autoimmune alveolar proteinosis (aPAP). On November 1, 2023, the clinical trial officially kicked off, with Jiuzhitang Maker collaborating with the First Affiliated Hospital of Guangzhou Medical University to conduct a Phase IIa clinical study evaluating hBMMSC therapy for treating aPAP. This marks Jiuzhitang Maker’s first domestically developed Class I biologic product—a novel stem-cell drug—and also represents the world’s first clinical trial exploring human bone marrow mesenchymal stem cells as a treatment for autoimmune alveolar proteinosis (aPAP).

In March 2025, Jiuzhitang Maker received approval (Acceptance No.: CXSL2400859) for the Phase III clinical trial of its third stem-cell-based new drug, targeting autism spectrum disorder. On August 26, 2025, the clinical trial officially kicked off, with Jiuzhitang Maker collaborating with Beijing Anding Hospital to conduct a Phase I clinical study evaluating hBMMSC therapy for autism spectrum disorder. This marks the country’s first-ever clinical trial exploring the use of human bone marrow mesenchymal stem cells as a treatment for autism.

On October 28, 2025, Jiuzhitang Maker established a wholly-owned subsidiary in Guangzhou's Nansha District—Jiuzhitang Maker (Guangzhou) Cell Technology Co., Ltd.

In the future, Jiuzhitang Maker will uphold Jiu Zhitang’s over-370-year-old family motto—“A pharmacist should dedicate their utmost effort, and a physician should act with a clear conscience”—while fully leveraging its advanced production technologies and industrialization capabilities to actively drive the launch of stem-cell-based drugs in the domestic market.